ITM 177Lu-Edotreotide CRL: Manufacturing Only

The FDA handed German radiopharmaceutical firm ITM Isotope Technologies Munich a Complete Response Letter on August 7 for 177Lu-edotreotide (ITM-11), its radioligand therapy for gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The company disclosed the rejection on August 10. The CRL cited chemistry, manufacturing, and controls (CMC) items plus findings from an inspection of a third-party commercial facility, and raised no clinical, nonclinical, or safety concerns.

The clinical case was already settled. In the Phase 3 COMPETE trial (NCT03049189), 309 patients with Grade 1 or Grade 2 somatostatin-receptor-positive GEP-NETs were randomized 2:1 to 177Lu-edotreotide or everolimus. The drug extended median progression-free survival to 23.9 months versus 14.1 months, a hazard ratio of 0.67 (95% CI, 0.48 to 0.95; p=0.022). The objective response rate was 21.9% versus 4.2%. An interim overall survival analysis trended favorably at 63.4 versus 58.7 months but did not reach statistical significance.

177Lu-edotreotide pairs non-carrier-added lutetium-177, a beta-emitting isotope, with edotreotide, a somatostatin receptor agonist, so it delivers targeted radiation to neuroendocrine tumor cells. The “non-carrier-added” label matters: it means the isotope is produced at high specific activity, unlike the carrier-added lutetium used in some older radioligands. Patients received 7.5 gigabecquerels every three months for up to four cycles.

GEP-NETs are rare, slow-growing tumors of the digestive tract and pancreas, so the addressable patient pool is small. If approved, 177Lu-edotreotide would compete with Novartis’s Lutathera (lutetium Lu 177 dotatate), the only other radioligand therapy cleared for somatostatin-receptor-positive GEP-NETs, which has been on the market since January 2018.

For investors, the rejection is a reminder that radiopharmaceuticals carry a manufacturing risk ordinary small molecules do not. Radioisotopes decay, so every dose must be produced, quality-checked, and shipped on a tight schedule. A finding at a third-party facility can stall an otherwise approvable drug. The sector has been consolidating around this exact supply-chain thesis — Curium’s $8 billion agreement to acquire Lantheus and the radiopharma franchise Novartis built around Pluvicto both turn on manufacturing and isotope supply.

ITM is privately held, so there is no ticker to trade. The company has funded its pipeline through equity raises and up to $262.5 million in non-dilutive debt from Blue Owl-managed funds, and it said it intends to resubmit the application. Because the FDA flagged no clinical issues, a resubmission would not require new patient data.

What to watch next: how quickly ITM resolves the facility findings and refiles. A resubmission with no new clinical data keeps the approval path intact, but the clock matters in a market where Lutathera is already entrenched.

Source: ITM complete response letter for 177Lu-edotreotide press release